Start with the evidence currently retained.
One glance at identity, filing chronology and source layers before opening the full issuer dossier.
Official reference points for this company.
This page distinguishes the earliest retained official filing from an issuer’s first public trading or initial quotation date. Missing history is not a conclusion about the issuer.
Tarsier Pharma Ltd.
Business context
Official filing overview: We are a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet need in ocular diseases with underlying inflammatory pathologies.
Newly detected public-record events
Events first captured by this monitoring workflow for this CIK. Open the source and the filing brief before making any legal, diligence or transaction conclusion.
- F-1/ATarsier Pharma Ltd.Official source →
- F-1/ATarsier Pharma Ltd.Official source →
- F-1/ATarsier Pharma Ltd. (TARX)Official source →
- F-1/ATarsier Pharma Ltd. (TARX)Official source →
Evidence chain for this issuer
Built from 4 captured SEC filing nodes, from 2026-05-18 through 2026-07-16. It shows what has been observed in the record and what still needs independent verification.
- Identity anchorCIK 0002102720 · issuer name carried from the SEC filing history
- Registration entryNo initial S-1 / F-1 is in the captured record
- Amendment trail4 amendments captured
- Effectiveness / prospectusNo EFFECT or 424B is in the captured record
- Ongoing record watchLatest captured form: F-1/A on 2026-07-16
CIK and issuer name are linked to the captured SEC filing sequence.
Not present in the currently captured SEC record. This is not a negative finding.
4 amendments captured for comparison.
Not present in the currently captured SEC record. This is not a negative finding.
Verification queue
- Confirm current legal entity, officers, directors and control from the controlling filing and corporate records.
- Review capitalization, transfer-agent information and any beneficial-ownership questions through the client’s qualified advisers.
- Compare material business, financing and risk disclosure changes in the official source documents.
Source boundary
Forms captured: F-1/A. This is an evidence map, not a safety rating, shell determination, legal opinion, valuation or transaction recommendation. Absence from a captured source is never proof that a fact does not exist.
Open Evidence Snapshot →Need a documented diligence trail?
Use this issuer dossier as the starting evidence layer. A defined scope can package the official filing history, public company actions and questions for your independently retained advisers to review.
What changed in the filing path
Relationship cues are generated from the order and form type of retained official filings. They are not a clause-by-clause document redline; verify terms in the linked source.
- Registration pathF-1/A
Amendment form captured; no prior same-lane filing is retained in this timeline
Open official filing →
Comparable filing terms
Machine comparison found 2 retained filing pairs with comparable term-text differences. These are extracted text windows, not a definitive legal or economic comparison. Official filings control.
- F-1/A · 2026-07-16Compared with F-1/A · 2026-06-08
Offer size / shares
Earlier extract: [●], 2026, VOID AFTER 5:00 P.M., EASTERN TIME, [●], 2031. WARRANT TO PURCHASE ORDINARY SHARES TARSIER PHARMA LTD. Warrant Shares: _______ Initial Exercise Date: ______, 2026 THIS WARRANT TO PURCHASE ORDINARY SHARES (the “ Warrant ”) cer
Later extract: g, the Company will effect an 10 -for-1 forward stock split of its issued and outstanding ordinary shares (the “Forward Stock Split”). As a result of the Forward Stock Split, each issued and outstanding ordinary share immediately prior to the eff
Offering price
Earlier extract: e may be less than the amount stated on the face hereof. b) Exercise Price . The exercise price per share of the Ordinary Shares under this Warrant shall be $_______, subject to adjustment hereunder (the “ Exercise Price ”). 1 c) Cashless Exercise
Later extract: r value NIS 0.001 per share (the “ordinary shares”). We anticipate that the initial public offering price of our ordinary shares will be between $8.00 and $10.00, and the number of our ordinary shares offered hereby is based upon an assumed offer
Open later official filing →Underwriting arrangement
Earlier extract: EX-4.2 3 ea027016609ex4-2.htm FORM OF UNDERWRITER WARRANT Exhibit 4.2 Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS REPRESENTATIVE’S WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS
Later extract: ering. The offering is being underwritten on a firm commitment basis. We have granted the underwriter an option to buy up to an additional 833,333 ordinary shares to cover over -allotments . The underwriter may exercise this option at any time and from time to
- F-1/A · 2026-06-08Compared with F-1/A · 2026-05-18
Offer size / shares
Earlier extract: Company intends to effect an 10 -for-1 forward stock split of its issued and outstanding ordinary shares (the “Forward Stock Split”). As a result of the Forward Stock Split, each issued and outstanding ordinary share immediately prior to the effe
Later extract: [●], 2026, VOID AFTER 5:00 P.M., EASTERN TIME, [●], 2031. WARRANT TO PURCHASE ORDINARY SHARES TARSIER PHARMA LTD. Warrant Shares: _______ Initial Exercise Date: ______, 2026 THIS WARRANT TO PURCHASE ORDINARY SHARES (the “ Warrant ”) cer
Offering price
Earlier extract: r value NIS 0.001 per share (the “ordinary shares”). We anticipate that the initial public offering price of our ordinary shares will be between $8.00 and $10.00, and the number of our ordinary shares offered hereby is based upon an assumed offer
Later extract: e may be less than the amount stated on the face hereof. b) Exercise Price . The exercise price per share of the Ordinary Shares under this Warrant shall be $_______, subject to adjustment hereunder (the “ Exercise Price ”). 1 c) Cashless Exercise
Open later official filing →Underwriting arrangement
Earlier extract: ering. The offering is being underwritten on a firm commitment basis. We have granted the underwriter an option to buy up to an additional 750,000 ordinary shares to cover over -allotments . The underwriter may exercise this option at any time and from time to
Later extract: EX-4.2 3 ea027016609ex4-2.htm FORM OF UNDERWRITER WARRANT Exhibit 4.2 Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS REPRESENTATIVE’S WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS
Save a dated issuer evidence record.
When this company needs to move from a live review into a client, counsel, broker-dealer or internal file, generate the current source-linked Evidence Snapshot.
Official filing chronology · change cues · printable HTML · CSV source indexResearch routes for this issuer
Use the issuer chronology for the record. These focused indexes make it easier to compare the same official filing type across the monitored OTC universe.
What to review next
Rules are applied to retained SEC filing types in this issuer record. They prioritize reading work; they are not ratings or conclusions.
- WATCHF-1/A2026-07-16 · form-type review cueSEC source →
- WATCHF-1/A2026-07-15 · form-type review cueSEC source →
- WATCHF-1/A2026-06-16 · form-type review cueSEC source →
- WATCHF-1/A2026-06-08 · form-type review cueSEC source →
- WATCHF-1/A2026-05-18 · form-type review cueSEC source →
Official filing timeline
- F-1/A · official filing
Tarsier Pharma Ltd.
- F-1/A · official filing
Tarsier Pharma Ltd.
- F-1/A · official filing
Tarsier Pharma Ltd. (TARX)
- F-1/A · official filing
Tarsier Pharma Ltd. (TARX)
Need a dated issuer evidence chain?
Generate a source-linked Shell Readiness File for first-pass internal screening. It organizes public records; it does not determine shell status or transaction feasibility.
Verify beyond this monitor.
These links open third-party official sources. They do not imply a match, a current quotation, a legal finding, or an OTC Markets data license.
What this dossier currently contains.
“Not retained” means this monitor does not currently hold a matching record in the named source layer. It does not establish absence, quotation status, compliance status, or issuer quality.
Retained SEC record, including historical submissions.
Recent filings are retained from the SEC submissions index. On dossier visits, the monitor also checks the SEC’s older submission archive in the background. This is a filing-history view—not a quotation, trading, financing-close or capitalization record.
Historical archive check pending retry. 2026-09-19 12:14 UTC. “Not retained” or a low count means this monitor has not stored a matching filing; it does not establish absence of a filing or issuer activity.
Official release-title candidates, not a risk label.
The SEC describes Litigation Releases as records concerning civil actions brought by the Commission in federal court. This monitor checks only the SEC’s official release feed and only surfaces a strict company-name title candidate for human review.
Issuer name is too short for conservative automatic matching. Feed cache: 2026-09-19 07:15 UTC.
A candidate does not confirm that this issuer is a respondent, defendant, affiliate, currently subject to an action, or associated with a filing. Names can overlap or change. Open the official SEC source and independently verify legal identity, entity status and context.
Names retained under this CIK.
These names come from the SEC submissions record and are useful identity clues when reviewing older filings or release titles. They do not independently prove a merger, reverse merger, ticker change, transaction date or continuity of business.
- Tarsier Pharma Ltd.Current SEC submission name
Latest retained dollar facts, with period context.
Values come directly from SEC Companyfacts. Different facts can have different reporting periods or filing dates, so they are not combined into ratios or performance conclusions.
Source check: 2026-09-18 18:40 UTC. “Not retained” means no compatible USD fact was stored by this monitor; it does not establish that the company has no revenue, cash, assets, filings, operations or reporting obligation. Open the SEC filing for full context.
Source-bound professional discussion.
Research Notes keep observations, questions and correction requests attached to the official-record workflow. This discussion layer is not a recommendation, valuation, legal conclusion or trading venue.
Prepare a source-led update from this record.
Open the Newsroom Kit with this CIK already selected. It creates editable public-record drafts, a source citation and a review handoff—never a published release or a statement of issuer approval.
Company press releases
此区域仅收录公司新闻稿、公司公告或官网发布内容,不重复 SEC 申报动态。当前可先通过 OTC Markets 公司新闻页查看原文。
打开 OTC Markets 新闻原文 ↗Company press releases
公司新闻稿与公告将按公开来源归档;SEC 申报动态继续保留在原有 SEC 模块。
查看新闻稿入口 →Company press releases
Source available · Last updated: 2026/9/19 12:15:08
No press releases cached for this company.
View all press releases →